| |
CAB with GnRH antagonist
|
CAB with GnRH agonist
| |
|---|
|
n = 34
|
n = 50
|
P-value
|
|---|
|
Median age at diagnosis years (range)
|
75(50–88)
|
74 (55–85)
|
0.09†
|
|
≥ 75 years old (%)
| |
19 (56)
|
22 (44)
|
0.28‡
|
|
Median pretreatment PSA level ng/mL (range)
| |
176.4 (51.5–5076)
|
136.4 (51.9–5827)
|
0.82†
|
|
Pathological diagnosis
|
Gleason score 6
|
1
|
2
|
0.78‡
|
|
Gleason score 7
|
9
|
8
|
|
Gleason score 8
|
11
|
21
|
|
Gleason score 9
|
11
|
16
|
|
Gleason score10
|
2
|
3
|
|
No of Gleason score 8–10 (%)
| |
24(70)
|
40(80)
|
0.19‡
|
|
T category
|
T2
|
4
|
9
|
0.60‡
|
|
T3
|
24
|
33
|
|
T4
|
6
|
7
|
|
Unknown
|
0
|
1
|
|
Bone metastasis
|
EOD0
|
16
|
22
|
0.72‡
|
|
EOD1
|
7
|
9
|
|
EOD2
|
8
|
10
|
|
EOD3
|
3
|
6
|
|
EOD4
|
0
|
1
|
|
Unknown
|
0
|
2
|
|
Lymph node metastasis (%)
|
Positive
|
21 (62)
|
25 (50)
|
0.58‡
|
|
Negative
|
13 (38)
|
23 (46)
| |
|
Unknown
|
0
|
2
| |
|
When to use bicalutamide
|
Concurrently
|
15
|
12
| |
|
Before
|
19
|
38
| |
|
Median observation period days (range)
| |
761 (212–1529)
|
1141(175–3419)
|
< 0.01*
|
- †: Wilcoxon’s rank sum test, ‡: Chi-square test, *: Log-rank test
- CAB combined androgen blockade, EOD the extent of disease, GnRH gonadotropin-releasing hormone, PSA prostate-specific antigen
- EOD stratification
- EOD grade 0; normal and benign bone disease
- EOD grade 1; number of bone metastases < 6
- EOD grade 2; number of bone metastases 6–20
- EOD grade 3; number of bone metastases > 20 but less than “super scan”
- EOD grade 4; super scan
